ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

Published:2018-03-15 Issue:6 Volume:17 Page:1156-1166
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Patel Hetal,Periyasamy Manikandan,Sava Georgina P.,Bondke Alexander,Slafer Brian W.,Kroll Sebastian H. B.,Barbazanges Marion,Starkey Richard,Ottaviani Silvia^ORCID,Harrod Alison,Aboagye Eric O.,Buluwela Laki,Fuchter Matthew J.,Barrett Anthony G. M.,Coombes R. Charles,Ali Simak

Funder

Cancer Research UK

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7);European Journal of Medicinal Chemistry;2024-10

2. Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023);Pharmaceutical Fronts;2024-09-03

3. Cancer plasticity in therapy resistance: Mechanisms and novel strategies;Drug Resistance Updates;2024-09

4. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

5. Cimicifugin, a broad-spectrum inhibitor of Theileria annulata and Plasmodium falciparum CDK7;Antimicrobial Agents and Chemotherapy;2024-08-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP